Bluebird Bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy

Bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene autotemcel, also known as lovo-cel) with the state of Michigan.